Avidity Biosciences Partners with Orna Therapeutics on BCMA-Targeted RNA Therapeutics for Myeloma

Orna Therapeutics and Simnova Collaborate on BCMA-Targeted RNA Therapeutics

Orna Therapeutics, Inc. has recently expanded its strategic collaboration with Shanghai Simnova Biotech Co., Ltd. to include B-cell maturation antigen (BCMA) as a target for RNA-based therapeutics. This partnership leverages Orna's cutting-edge circular RNA (oRNA®) technology and Simnova's extensive expertise in cell therapy. Together, they aim to develop transformative treatments for patients suffering from multiple myeloma, which is significantly underserved in terms of effective therapies. The agreement outlines that Simnova will spearhead research, development, and commercialization of in vivo panCar cell therapies targeting BCMA in Greater China, while Orna retains the rights to these innovations for the rest of the world.

The collaboration builds upon an earlier agreement established in January 2023, which granted Simnova exclusive rights to develop Orna's in vivo cell therapy products in Greater China, including Orna’s lead isCAR project, "ORN-101," aimed at targeting CD19. The recent expansion signifies both companies' commitment to advancing innovative therapies that address the pressing needs of multiple myeloma patients. Ansbert Gadicke, M.D., Chairman of Orna, expresses enthusiasm about this collaboration, noting the potential of their panCAR approach to overcome the limitations of existing ex vivo cell therapies. This sentiment reflects a growing recognition within the biopharmaceutical industry of the need for new modalities that can enhance the efficacy and accessibility of cancer treatments.

Dr. Zhuoxiao Cao, CEO of Simnova, underscores the importance of their shared dedication to immunotherapy as a means to tackle unmet medical needs. This partnership not only highlights the strengths of both companies but also represents a significant step forward in the development of BCMA-targeted therapeutics. As Orna Therapeutics continues to innovate in the realm of RNA medicine, the collaboration with Simnova positions both companies to potentially reshape the treatment landscape for patients with multiple myeloma, offering hope for improved outcomes through their advanced therapeutic approaches.

In addition to the collaboration, Orna's focus on designing circular RNA therapeutics exemplifies a shift toward innovative RNA-based treatments that promise simplified production processes and enhanced protein expression. This development is crucial as the field of RNA medicine evolves, offering new avenues for patient care that could lead to more effective therapies for a variety of diseases.

As the biopharmaceutical industry continues to innovate, partnerships such as the one between Orna and Simnova showcase the potential for advancements in personalized medicine and targeted therapies, which are essential in addressing the challenges posed by complex diseases like multiple myeloma. The strategic collaboration not only signifies a commitment to scientific progress but also reflects a broader trend toward collaborative approaches in drug development.